Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atossa Genetics

0.7326
-0.0054-0.73%
Volume:610.71K
Turnover:446.39K
Market Cap:94.63M
PE:-3.62
High:0.7576
Open:0.7540
Low:0.7111
Close:0.7380
Loading ...

Company Profile

Company Name:
Atossa Genetics
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
15
Office Location:
107 Spring Street,Seattle,Washington,United States
Zip Code:
98104
Fax:
206 902 9658
Introduction:
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Directors

Name
Position
Steven C. Quay
Chairman of the Board, President and Chief Executive Officer
Gregory L. Weaver
Director
H. Lawrence Remmel
Director
Richard I. Steinhart
Director
Shu Chih Chen
Director
Stephen J. Galli
Director

Shareholders

Name
Position
Steven C. Quay
Chairman of the Board, President and Chief Executive Officer
Kyle Guse
Chief Financial Officer, General Counsel and Secretary